COVID-19 early curative treatments in kidney transplant recipients: Is it really reasonable in the Omicron era? (notice n° 191664)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02504cam a2200289 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112044658.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Tamzali, Yanis |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | COVID-19 early curative treatments in kidney transplant recipients: Is it really reasonable in the Omicron era? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2023.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 38 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Objective. Data about the efficacy and safety of the latest COVID-19 treatments, nirmatrelvir/ritonavir (n/r) and sotrovimab, is scarce in solid organ transplant recipients in the Omicron era. This study aims to describe the outcome of kidney transplant recipients (KTRs) presenting Omicron infection according to their management: n/r, sotrovimab, or no specific treatment. Patients and methods. We conducted a monocentric, retrospective observational study, including KTRs diagnosed with Omicron infection between January and May 1, 2022 and compared their outcome (primary outcome defined as hospital admission for COVID-19 within a month after symptoms onset) according to early COVID-19 management. Results. Forty-five patients were included: 22 treated (12 n/r, 10 sotrovimab) and 23 with no specific treatment. The groups were statistically comparable. Two patients were admitted for COVID-19: one in each group, resulting in a non-different probability of the primary outcome at one month (p=0.9). Three patients presented with tacrolimus overdose, and two of these patients also presented with acute kidney injury. Conclusions. There was no difference in outcome depending on whether patients had early treatment with n/r, sotrovimab, or whether they had no specific treatment. Our study both highlights a decreased severity of Omicron COVID-19 in KTRs (probably related to vaccinal immunity and the decreased virulence of Omicron) and the potential severe adverse effects of n/r. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lundy, Alexia |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bleibtreu, Alexandre |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cazenave, Maud |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mohammadou, Inna |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Arzouk, Nadia |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Galichon, Pierre |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Marot, Stéphane |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Junot, Helga |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Barrou, Benoît |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pourcher, Valérie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tourret, Jérôme |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Néphrologie & Thérapeutique | Volume 19 | 6 | 2023-06-01 | p. 491-496 | 1769-7255 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-nephrologie-therapeutique-2023-6-page-491?lang=en">https://shs.cairn.info/journal-nephrologie-therapeutique-2023-6-page-491?lang=en</a> |
Pas d'exemplaire disponible.
Réseaux sociaux